RemeGen stock | 2026 price target, earnings & valuation

RemeGen

SEHK:9995

HK$ 95,80

HK$-3,05 (-3,09%)

95,80 HK$

HK$-3,05 (-3,09%)

End-of-day quote: 03/31/2026

RemeGen Stock Value

Currently, analysts rate RemeGen as Outperform.

Outperform

RemeGen Company Info

EPS Growth 5Y

22,38%

Market Cap

HK$72,41 B

Long-Term Debt

HK$1,20 B

Annual earnings

N/A

Dividend

HK$0,00

Dividend Yield

0,00%

Founded

2008

Industry

Health Care

Country

China

Website

RemeGen

ISIN Number

CNE1000048G6

Website

http://www.remegen.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

HK$105,75

10.39%

Last Update: 03/31/2026

Analysts: 15

Highest Price Target HK$143,80

Average Price Target HK$105,75

Lowest Price Target HK$51,94

In the last five quarters, RemeGen’s Price Target has risen from HK$8,91 to HK$35,19 - a 294,95% increase. Five analysts predict that RemeGen’s share price will increase in the coming year, reaching HK$105,75. This would represent an increase of 10,39%.

Top growth stocks in the health care sector (5Y.)

What does RemeGen do?

RemeGen Co., Ltd. (RemeGen) integrates biopharmaceutical company dedicates to the discovery, development, and commercialization of innovative biologics aimed at treating autoimmune diseases, oncology, and ophthalmic conditions, particularly focusing on unmet medical needs. Business Segments The company operates in various segments focused on biopharmaceuticals, including research and development (R&D) of innovative biologics and commercialization in the healthcare market. The primary activitie...

Business Segments

The company operates in various segments focused on biopharmaceuticals, including research and development (R&D) of innovative biologics and commercialization in the healthcare market. The primary activities involve the conceptualization and production of drugs that cater to critical medical exigencies. RemeGen's advancements in R&D have enabled it to introduce several drug candidates at various stages, including clinical trials and market preparations.

In the autoimmune segment, RemeGen has focused on creating therapies that address prevalent conditions, employing a targeted approach to develop treatments that are effective and differentiated in their method of action. The oncology segment highlights RemeGen's commitment to combat various types of cancer through innovative therapies aimed at precision medicine, thus enhancing treatment efficacy and patient quality of life. The ophthalmic segment addresses vision-related ailments, showcasing the company's versatility in its therapeutic approach.

RemeGen has successfully navigated the complexities of the biopharmaceutical industry, especially in China, where regulatory adherence and rapid innovation are essential for growth and sustainability. The company's pipeline reflects its strategic focus on areas with significant unmet needs, characterized by high patient demand and potential market opportunities.

Recent developments and milestones highlight successful submissions and approvals from the National Medical Products Administration (NMPA) for novel therapies including telitacicept and disitamab vedotin, which further exemplify the company's rigorous R&D efforts. The proactive approach to clinical studies, collaborations with various stakeholders, and adaptations to market dynamics have enabled RemeGen to solidify its market position and engage effectively with healthcare systems globally.

Business Strategy

The company's strategy revolves around leveraging its R&D capabilities to generate a robust pipeline of innovative therapeutics designed to meet significant medical needs. By focusing on biologics, RemeGen aims to differentiate itself in a crowded marketplace by offering cutting-edge treatments that provide better efficacy and potentially fewer side effects compared to conventional medications.

In the execution of its business strategy, RemeGen emphasizes collaboration and strategic partnerships with academic institutions and other biotech firms, allowing for shared resources and expertise that accelerate the discovery and development process. This collaborative ecosystem also facilitates access to advanced technologies and methodologies that are pivotal in drug development.

RemeGen also adopts a patient-centric approach, focusing on delivering medications that improve patient outcomes and overall quality of life. By engaging healthcare professionals and conducting comprehensive market assessments, RemeGen ensures that its products are aligned with real-world medical practices and patient needs.

Furthermore, the company's emphasis on adhering to regulatory requirements is fundamental to its strategy, driving compliance and ensuring that R&D activities are aligned with the latest industry standards. This proactive stance towards regulatory adherence mitigates risks and fosters trust and integrity in its interactions with stakeholders.

Products and Services

RemeGen is committed to delivering innovative biopharmaceutical products that address significant healthcare challenges. The company's product offerings include various biologic therapies that are at different stages of the drug development lifecycle. Notable products in RemeGen's pipeline include telitacicept and disitamab vedotin, which have received approvals from the NMPA.

Telitacicept, specifically designed for autoimmune diseases, has shown promising efficacy in numerous clinical trials, paving the way for its commercial introduction in China. Disitamab vedotin targets oncology markets, representing the company's dedication to advancing cancer treatment through innovative therapies. In addition, RemeGen is involved in the research and development of other drug candidates aimed at treating conditions in the ophthalmic sector.

The company places a strong emphasis on ensuring high quality and safety standards in its manufacturing processes, aligning with international regulatory standards. All RemeGen products undergo rigorous testing and compliance verification before they reach the market. This commitment to quality is an integral part of the company's identity as a reliable pharmaceutical entity.

RemeGen also remains focused on continuous improvement and iterative development based on patient feedback and clinical outcomes. It champions a proactive approach to integrating technological advancements into its production processes, ensuring that products are developed using the most efficient and effective methodologies.

Geographical Markets Served

RemeGen primarily serves the Chinese market, leveraging its established position in the biopharmaceutical sector. However, the company is actively exploring opportunities for international expansion, with strategic intentions to penetrate global markets. By diversifying its reach beyond domestic borders, RemeGen aims to tap into new patient populations and enhance its market presence.

RemeGen's R&D teams are integrated to ensure that products meet varied regulatory requirements across different geographical markets, thus streamlining the pathway for market entry in countries beyond China. The global biopharmaceutical landscape provides a fertile ground for RemeGen's innovative therapies, and the company is keen to establish robust distribution networks to facilitate this expansion.

Seasonality

The biopharmaceutical sector typically exhibits less seasonal variance compared to other industries, as patient needs for medication remain consistent throughout the year.

Customers

RemeGen focuses on various customer segments including healthcare providers, hospitals, and clinics that utilize its biopharmaceutical products. By establishing strong relationships with a broad range of customers, the company aims to ensure that its innovative therapies are accessible to patients who need them. Furthermore, RemeGen engages with healthcare professionals and institutions directly to promote its product offerings and education about the innovative treatments available. This ongoing communication fosters loyalty and assists in gathering valuable insights into patient and provider needs.

Sales and Marketing

The company's marketing strategy is multi-faceted, employing direct sales forces to build relationships with healthcare providers. RemeGen also utilizes digital marketing strategies to enhance its outreach and engagement, thereby effectively communicating its product offerings and innovations. Distribution channels are strategically developed, ensuring that products reach healthcare facilities efficiently. RemeGen's marketing initiatives are designed to educate and inform both patients and healthcare professionals about the therapeutic benefits of its products, thereby fostering understanding and uptake.

History

RemeGen Co., Ltd. was founded in 2008. The company was incorporated in 2008.

RemeGen Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Sales:** 100% (2025) **TOP 3 Markets:** 1. **China:** approx. 70% 2. **USA:** approx. 20% 3. **Europe:** approx. 10% RemeGen Co., Ltd. is a biopharmaceutical company specializing in the research, development, and marketing of innovative drugs. The majority of sales come from the p...

At which locations are the company’s products manufactured?

**Production Sites:** Yantai, China RemeGen Co., Ltd. mainly produces its biopharmaceutical products in Yantai, China. The company has established modern production facilities there to manufacture its innovative medicines, especially in the field of antibody therapies. This strategic location choic...

What strategy does RemeGen pursue for future growth?

**Focus on Research and Development:** RemeGen invests heavily in R&D to develop innovative biopharmaceutical products. **International Expansion:** The company plans to expand its presence in global markets, especially in the USA and Europe. **Partnerships and Collaborations:** RemeGen aims t...

Which raw materials are imported and from which countries?

**Main raw materials:** Biopharmaceutical active ingredients, laboratory chemicals **Main importing countries:** USA, Germany, Switzerland RemeGen Co., Ltd., a biopharmaceutical company, mainly imports biopharmaceutical active ingredients and special laboratory chemicals needed for the research a...

How strong is the company’s competitive advantage?

**Market Share in Biotechnology:** Estimated 5-7% (2025) **R&D Investments:** 20% of revenue (2024) RemeGen Co., Ltd. has gained a significant competitive advantage through its strong investments in research and development. With approximately 20% of revenue allocated to R&D, the company p...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** Approximately 45% (estimated for 2025 based on trends) **Insider Buys/Sells:** No significant transactions in the last year (2024) The institutional investor share in RemeGen Co., Ltd. is estimated to be around 45%. This reflects the confidence of institutional in...

What percentage market share does RemeGen have?

**Market share of RemeGen Co., Ltd.:** Estimate 3-5% (2025) **Top competitors and their market share:** 1. **Roche Holding AG:** approx. 15% 2. **Novartis AG:** approx. 12% 3. **Pfizer Inc.:** approx. 10% 4. **Johnson & Johnson:** approx. 9% 5. **Merck & Co., Inc.:** approx. 8% 6. **Bristol...

Is RemeGen stock currently a good investment?

**Revenue Growth:** 18% (2024) **Research and Development Ratio:** 30% of revenue (2024) **Market Share in the Biotechnology Industry:** 5% (2024) RemeGen Co., Ltd. achieved an impressive revenue growth of 18% in 2024, attributed to the successful launch of new biopharmaceutical products and expans...

Does RemeGen pay a dividend – and how reliable is the payout?

**Dividend payment:** No dividend (2025) RemeGen Co., Ltd. has not paid any dividends so far. The company is in a growth phase and reinvests its profits in research and development as well as market expansion. For investors aiming for dividend income, RemeGen may currently be less attractive. Howe...

New support ticket

Explore

RemeGen Stock Value

RemeGen Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does RemeGen do?

RemeGen Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

RemeGen Stock Value

RemeGen Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does RemeGen do?

RemeGen Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.